Subscribe
Patients with early breast cancer and a low Oncotype DX recurrence score can safely receive treatment with hormone therapy alone and avoid chemotherapy, according to results of the TAILORx trial, which was sponsored by the National Cancer Institute.
As patients, providers, payers, and policymakers continue to seek ways to assess the value of cancer therapies by balancing clinical benefits and treatment costs, a number of tools have been released to define the value of medicines.
Much attention is given to how bad news affects patients with cancer. Yet, little is known about the experience of physicians and what is required by them to deliver this news.
The Triple Aim of better patient care, lower spending by payers, and the maintenance of financially viable practices and hospitals is achievable with condition-based payment models in oncology, said Harold D. Miller, MS, President and Chief Executive Officer, Center for Healthcare Quality and Payment Reform, at the Fifth Annual Conference of the Association for Value-­Based Cancer Care.
  • A Turning Point in Cancer Therapy: First Combination of 2 Immunotherapies Approved for Advanced Melanoma
  • Another Immunotherapy, Keytruda, Approved for Metastatic Lung Cancer Together with a Companion Diagnostic
  • Lonsurf, a New Oral Combination, Approved for Patients with Metastatic Colorectal Cancer
  • Emend Receives Expanded Indication for CINV Prevention in Pediatric Patients
The American Society of Clinical Oncology (ASCO) recently issued its framework to assess the value of cancer treatment options in response to the major challenge of escalating healthcare costs in the United States.
Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).
Copenhagen, Denmark—Biosimilar filgrastim (Nivestim; Hospira), which was approved earlier this year by the European Commission but not yet by the FDA, showed effectiveness for the treatment of neutropenia and febrile neutropenia (FN) in patients undergoing cytotoxic chemotherapy for solid tumors and hematologic malignancies, according to a study presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology meeting.
The treatment of patients with colorectal cancer (CRC) may benefit from immunotherapy with anti–PD-1 agents, based on results of a recent study using pembrolizumab (Keytruda).
The treatment of patients with brain metastases involves issues of controlling recurrence, side effects, and costs.
Page 1 of 2
Results 1 - 10 of 13
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology